Compared to other HDAC inhibitors, the superiority of tucidinostat for PTCL is reflected in many aspects such as effectiveness, synergistic effect with immunotherapy, safety, convenience and economy (Lu et al., 2016). Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.